Results 201 to 210 of about 164,679 (343)

Pharmacological Microglial Inhibition Remodels the Scar Microenvironment to Support Reticulospinal Circuit Reconstruction After Spinal Cord Injury

open access: yesAdvanced Science, EarlyView.
This study establishes pharmacological microglial inhibition as a therapeutic strategy, demonstrating its capacity to remodel the lesion microenvironment through significant reduction of extracellular matrix deposition. This permissive environmental transformation facilitates robust regeneration of the reticulospinal tract, and reconstructs functional ...
Run Li   +11 more
wiley   +1 more source

Regulation of Neuroinflammation by Microglial DUBA‐IRAK1‐IKKβ Signaling Loop

open access: yesAdvanced Science, EarlyView.
The protein levels of deubiquitinating enzyme A (DUBA) are rapidly upregulated in microglia after activation of Toll‐like receptor 4 (TLR4). In turn, DUBA potentiates TLR4‐induced proinflammatory signal transduction in microglia by stabilizing interleukin‐1 receptor activated kinase 1 (IRAK1) through K48 deubiquitination.
Zhenhu Zhu   +22 more
wiley   +1 more source

Structural Studies on the O-Specific Side Chains of the Cell Wall Lipopolysaccharide from Salmonella bredeney. [PDF]

open access: bronze, 1969
Carl Gustaf Hellerqvist   +5 more
openalex   +1 more source

Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model

open access: yesAdvanced Science, EarlyView.
Nanographene oxide (NGO) attenuates graft‐versus‐host disease (GVHD) severity by inhibiting STAT1‐mediated M1 macrophage polarization and suppressing T‐cell activation. NGO‐primed macrophages (NGO‐Mac) further enhance regulatory T‐cell induction via IL‐10. Both NGO and NGO‐Mac therapies mitigate inflammation and immune pathology, offering cell‐free and
Aaron Yu   +18 more
wiley   +1 more source

A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors

open access: yesAdvanced Science, EarlyView.
A modular antimicrobial‐peptide‐based therapeutic system integrating membrane‐targeted selectivity, a conformation‐driven polyethylene glycolylated blocker, and serum‐stabilizing N‐cap is developed. The optimized conjugate 270 shows potent, rapid killing of the desired tumor cells, high serum stability, low off‐target toxicity, and broad applicability,
Tianxing Liu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy